Moderna Inc. (MRNA) shares saw a significant rise on Tuesday, climbing nearly 4% after Canadian regulators approved the company's updated COVID-19 vaccine, Spikevax KP.2. The vaccine, which targets the KP.2 variant of the virus (a descendant of the JN.1 variant), is now authorized for use in individuals aged six months and older by Health Canada.
This approval follows similar action by the U.S. Food and Drug Administration (FDA), which last month approved updated COVID-19 vaccines from Moderna, as well as Pfizer and BioNTech. The approval is crucial for Moderna as it looks to expand the distribution of its vaccine in North America.
Moderna has announced that deliveries of the Spikevax KP.2 to the Public Health Agency of Canada will begin shortly. The news comes as a positive development for the company, which has struggled with stock performance this year, with shares having lost more than 25% of their value since January.
Despite the year-to-date decline, Tuesday's rally shows investor confidence in Moderna’s ability to adapt its vaccines to emerging COVID-19 variants. As the biotech firm continues to secure regulatory approvals, its market prospects could improve with further global rollouts of the updated vaccine.
This approval follows similar action by the U.S. Food and Drug Administration (FDA), which last month approved updated COVID-19 vaccines from Moderna, as well as Pfizer and BioNTech. The approval is crucial for Moderna as it looks to expand the distribution of its vaccine in North America.
Moderna has announced that deliveries of the Spikevax KP.2 to the Public Health Agency of Canada will begin shortly. The news comes as a positive development for the company, which has struggled with stock performance this year, with shares having lost more than 25% of their value since January.
Despite the year-to-date decline, Tuesday's rally shows investor confidence in Moderna’s ability to adapt its vaccines to emerging COVID-19 variants. As the biotech firm continues to secure regulatory approvals, its market prospects could improve with further global rollouts of the updated vaccine.